248 related articles for article (PubMed ID: 18843458)
1. Changes in urinary NTX levels in patients with primary osteoporosis undergoing long-term bisphosphonate treatment.
Iba K; Takada J; Hatakeyama N; Ozasa Y; Wada T; Yamashita T
J Orthop Sci; 2008 Sep; 13(5):438-41. PubMed ID: 18843458
[TBL] [Abstract][Full Text] [Related]
2. Changes in bone resorption markers among Japanese patients with postmenopausal osteoporosis treated with alendronate and risedronate.
Takada J; Iba K; Imoto K; Yamashita T
J Bone Miner Metab; 2007; 25(2):142-6. PubMed ID: 17323185
[TBL] [Abstract][Full Text] [Related]
3. Reduction of urinary levels of N-telopeptide correlates with treatment compliance in women with postmenopausal osteoporosis receiving alendronate.
Palacios S; Neyro JL; Ferrer J; Villero J; Cañada E; Redondo E; Caloto MT; Nocea G;
Menopause; 2012 Jan; 19(1):67-74. PubMed ID: 21926927
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of urinary N-telopeptide of type I collagen measurements in the management of osteoporosis in clinical practice.
Baxter I; Rogers A; Eastell R; Peel N
Osteoporos Int; 2013 Mar; 24(3):941-7. PubMed ID: 22872068
[TBL] [Abstract][Full Text] [Related]
5. Prolonged bisphosphonate release after treatment in women with osteoporosis. Relationship with bone turnover.
Peris P; Torra M; Olivares V; Reyes R; Monegal A; Martínez-Ferrer A; Guañabens N
Bone; 2011 Oct; 49(4):706-9. PubMed ID: 21742070
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of alendronate and risedronate for postmenopausal osteoporosis.
Iwamoto J; Takeda T; Sato Y
Curr Med Res Opin; 2006 May; 22(5):919-28. PubMed ID: 16709313
[TBL] [Abstract][Full Text] [Related]
7. Potential excessive suppression of bone turnover with long-term oral bisphosphonate therapy in postmenopausal osteoporotic patients.
Iizuka T; Matsukawa M
Climacteric; 2008 Aug; 11(4):287-95. PubMed ID: 18645694
[TBL] [Abstract][Full Text] [Related]
8. Course of NTX changes under continuous bisphosphonate treatment in cases of NTX over-reduction due to long-term treatment with bisphosphonates.
Iba K; Takada J; Sasaki K; Wada T; Yamashita T
J Orthop Sci; 2011 Jan; 16(1):71-6. PubMed ID: 21290152
[TBL] [Abstract][Full Text] [Related]
9. Denosumab compared with risedronate in postmenopausal women suboptimally adherent to alendronate therapy: efficacy and safety results from a randomized open-label study.
Roux C; Hofbauer LC; Ho PR; Wark JD; Zillikens MC; Fahrleitner-Pammer A; Hawkins F; Micaelo M; Minisola S; Papaioannou N; Stone M; Ferreira I; Siddhanti S; Wagman RB; Brown JP
Bone; 2014 Jan; 58():48-54. PubMed ID: 24141036
[TBL] [Abstract][Full Text] [Related]
10. [The effect of risedronate treatment on bone turnover markers in patients with hip fracture].
Altintaş F; Ozkut AT; Beyzadeoğlu T; Eren A; Güven M
Acta Orthop Traumatol Turc; 2007; 41(2):132-5. PubMed ID: 17483649
[TBL] [Abstract][Full Text] [Related]
11. Response to oral bisphosphonates in subgroups of younger and older postmenopausal women.
Stovall DW; Beard MK; Barbier S; Chen E; Rosenberg E; de Papp AE
J Womens Health (Larchmt); 2010 Mar; 19(3):491-7. PubMed ID: 20141367
[TBL] [Abstract][Full Text] [Related]
12. Treatment with once-weekly alendronate 70 mg compared with once-weekly risedronate 35 mg in women with postmenopausal osteoporosis: a randomized double-blind study.
Rosen CJ; Hochberg MC; Bonnick SL; McClung M; Miller P; Broy S; Kagan R; Chen E; Petruschke RA; Thompson DE; de Papp AE;
J Bone Miner Res; 2005 Jan; 20(1):141-51. PubMed ID: 15619680
[TBL] [Abstract][Full Text] [Related]
13. Bisphosphonates for prevention of postmenopausal osteoporosis.
Ravn P
Dan Med Bull; 2002 Feb; 49(1):1-18. PubMed ID: 11894721
[TBL] [Abstract][Full Text] [Related]
14. Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate.
Eastell R; Barton I; Hannon RA; Chines A; Garnero P; Delmas PD
J Bone Miner Res; 2003 Jun; 18(6):1051-6. PubMed ID: 12817758
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of bisphosphonates in reducing fracture risk in postmenopausal osteoporosis.
Bilezikian JP
Am J Med; 2009 Feb; 122(2 Suppl):S14-21. PubMed ID: 19187808
[TBL] [Abstract][Full Text] [Related]
16. Serum NTX is a practical marker for assessing antiresorptive therapy for glucocorticoid treated patients with chronic kidney disease.
Hamano T; Fujii N; Nagasawa Y; Isaka Y; Moriyama T; Okada N; Imai E; Horio M; Ito T
Bone; 2006 Nov; 39(5):1067-1072. PubMed ID: 16781904
[TBL] [Abstract][Full Text] [Related]
17. [Prediction of changes in bone density during alendronate treatment in postmenopausal women].
Masaryk P; Stancíková M; Letkovská A; Rovenský J
Vnitr Lek; 2002 Oct; 48(10):943-7. PubMed ID: 16737141
[TBL] [Abstract][Full Text] [Related]
18. Intravenous zoledronic acid 5 mg in the treatment of postmenopausal women with low bone density previously treated with alendronate.
McClung M; Recker R; Miller P; Fiske D; Minkoff J; Kriegman A; Zhou W; Adera M; Davis J
Bone; 2007 Jul; 41(1):122-8. PubMed ID: 17468062
[TBL] [Abstract][Full Text] [Related]
19. Treatment with tiludronate has a similar effect to risedronate on Paget's disease activity assessed by bone markers and bone scintigraphy.
Peris P; Alvarez L; Vidal S; Martínez MA; Monegal A; Guañabens N
Clin Exp Rheumatol; 2007; 25(2):206-10. PubMed ID: 17543143
[TBL] [Abstract][Full Text] [Related]
20. Drug insight: Bisphosphonates for postmenopausal osteoporosis.
Chapurlat RD; Delmas PD
Nat Clin Pract Endocrinol Metab; 2006 Apr; 2(4):211-9; quiz following 238. PubMed ID: 16932286
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]